N′-(Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features

Journal of Medicinal Chemistry

Volumn 54, Issue 20, 2011, Pages 7030-7054

  Van Loevezijn, Arnold ^a   Venhorst, Jennifer ^a   Iwema Bakker, Wouter I ^a   De Korte, Cor G ^a   De Looff, Wouter ^a   Verhoog, Stefan ^a   Van Wees, Jan Willem ^a   Van Hoeve, Martijn ^a,b   Van De Woestijne, Rob P ^a   Van Der Neut, Martina A W ^a   Borst, Alice J M ^a   Van Dongen, Maria J P ^a   De Bruin, Natasja M W J ^a   Keizer, Hiskias G ^a,c   Kruse, Chris G ^a  

^a Chemical Design and Synthesis Unit   (Netherlands)

^b Astra Tech Benelux BV   (Netherlands)

^c Lipid Nutrition BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

N' (2 CHLOROPHENYLSULFONYL) N BENZYL 4 ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (2 CHLOROPHENYLSULFONYL) N ISOPROPYL 4 ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (2 CHLOROPHENYLSULFONYL) N PHENYL 4 ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (2 CHLOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (2,5 DICHLOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (2,6 DICHLOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROBENZOYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N (2,2,2 TRIFLUOROETHYL) 4 ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 3 METHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 4 METHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 5 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 5 (FURAN 2 YL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 5 (PYRIDIN 4 YL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 5 PHENYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N METHOXY 4 ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N METHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N PROPYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 CHLOROPHENYLSULFONYL) N,N DIMETHYL 4 ETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 FLUOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 METHOXYPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3 TOLYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3,4 DICHLOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (3,5 DICHLOROPHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' (ARYLSULFONYL)PYRAZOLINE 1 CARBOXAMIDINE DERIVATIVE; N' (PHENYLSULFONYL) N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N' [3 (TRIFLUOROMETHYL)PHENYLSULFONYL] N,4 DIETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMIDINE; LIGAND; N' (3 CHLOROPHENYLSULFONYL) N ETHYL 4,4 DIMETHYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; N'-(3-CHLOROPHENYLSULFONYL)-N-ETHYL-4,4-DIMETHYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBO XAMIDINE; PYRAZOLE DERIVATIVE; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SULFONAMIDE;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; CRICETULUS; GUINEA PIG; HAMSTER; IN VITRO STUDY; LIVER CELL; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; STEREOISOMERISM; SYNTHESIS; WISTAR RAT;

AMIDINES; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; GUINEA PIGS; HEPATOCYTES; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, MOLECULAR; PROTEIN BINDING; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 80054945957     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200466r     Document Type: Article

References (91)

1. Monsma, F. J., Jr.; Shen, Y.; Ward, R. P.; Hamblin, M. W.; Sibley, D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs Mol. Pharmacol. 1993, 43, 320-327 (Pubitemid 23081986)
2. Ruat, M.; Traiffort, E.; Arrang, J. M.; Tardivel-Lacombe, J.; Diaz, J.; Leurs, R.; Schwartz, J. C. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation Biochem. Biophys. Res. Commun. 1993, 193, 268-276 (Pubitemid 23199942)
3. Woolley, M. L.; Marsden, C. A.; Fone, K. C. 5-ht6 receptors Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 59-79
4. 6 receptor Drugs Future 2005, 30, 479
5. 6 receptors in learning and memory Trends Pharmacol. Sci. 2008, 29, 482-492
6. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108, 1614-1641 (Pubitemid 351796401)
7. 6 pharmacology inconsistencies Pharmacol., Biochem. Behav. 2011, 98, 169-172
8. Roth, B. L.; Hanizavareh, S. M.; Blum, A. E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology 2004, 174, 17-24 (Pubitemid 38925086)
9. 6 receptors: a novel target for cognitive enhancement Pharmacol. Ther. 2005, 108, 320-333 (Pubitemid 41691871)
10. 6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease Neurotherapeutics 2008, 5, 458-469 (Pubitemid 351952494)
11. 6 receptor antagonists for the treatment of Alzheimer's disease Curr. Top. Med. Chem. 2008, 8, 1035-1048
12. 6 receptor in cognitive function Neuropharmacology 2008, 55, 1015-1022
13. 6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia Curr. Opin. Drug Discovery Dev. 2008, 11, 642-654
14. 6 antagonists as potential treatment for cognitive dysfunction Drug Dev. Res. 2009, 70, 145-168
15. 6 antagonists Drugs Future 2009, 34, 969-975
16. 6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease Expert Rev. Neurother. 2009, 9, 1073-1085
17. 6 receptor antagonists as potential therapeutics for cognitive impairment Curr. Top. Med. Chem. 2010, 10, 207-221
18. 6 antagonists SB-271046 and SB-399885 increase basal and learning induced hippocampal ncam polysialylation Int. J. Neuropsychopharmacol. 2004, 7, 215
19. 6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats Neuropharmacology 2008, 54, 1166-1174
20. 6-receptor activation on rat brain BDNF and Arc mRNA expression Neuroscience 2007, 147, 778-785
21. Johnson, C. N.; Roland, A.; Upton, N. New symptomatic strategies in Alzheimer's disease Drug Discovery Today: Ther. Strategies 2004, 1, 13-19 (Pubitemid 40208003)
22. 6 receptor antagonist, SB-742457, in Alzheimer's disease Curr. Alzheimer Res. 2010, 7, 374-385
23. Weso?owska, A.; Jastrzêbska-Wiêsek, M. Behavioral pharmacology: potential antidepressant and anxiolytic properties Int. Rev. Neurobiol. 2011, 96, 49-71
24. 6 receptor antagonist SB-271046 in behavioral models of cognition Soc. Neurosci. Abstr. 2004, 776.19 (abstract)
25. Comery, T. A.; Schechter, L. E. Method for the Treatment of Cognitive Dysfunction. WO 2007/087151, 2007.
26. 6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat Br. J. Pharmacol. 2008, 155, 434-440
27. 6 receptor ligands as antidementia drugs Int. Rev. Neurobiol. 2011, 96, 163-187
28. Keefe, R. S. E.; Malhotra, A. K.; Meltzer, H. Y.; Kane, J. M.; Buchanan, R. W.; Murthy, A.; Sovel, M.; Li, C.; Goldman, R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial Neuropsychopharmacology 2008, 33, 1217-1228 (Pubitemid 351521707)
29. Marder, S. R.; Fenton, W.; Youens, K. Cognition in schizophrenia: the MATRICS initiative Am. J. Psychiatry 2004, 161, 25
30. 6 receptors in modulating brain neurochemsitry Int. Rev. Neurobiol. 2011, 96, 1-26
31. Neale, A. C.; Jenkins, H.; Amend, D.; Lesem, M. A 14-day, dose-escalation, double blind, randomized, placebo-controlled study of SGS-518 in adult patients with schizophrenia Neuropsychopharmacology 2005, 30, S54
32. 6 receptor ligands and their antipsychotic potential Int. Rev. Neurobiol. 2011, 96, 141-161
33. Batel, P. Addiction and schizophrenia Eur. Psychiatry 2000, 15, 115-122 (Pubitemid 30194155)
34. 6 receptors related to reward and reinforcement Int. Rev. Neurobiol. 2011, 96, 111-139
35. de Bruin, N. M. W. J.; van Loevezijn, A.; Wijnen, J.; Herremans, A. H. J.; Kruse, C. G. Use of 5-HT6 Antagonists To Prevent Relapse into Addiction. WO 2008/087123, 2008.
36. 6 antagonism attenuates cue-induced relapse to cocaine seeking without affecting cocaine reinforcement Int. J. Neuropsychopharmacol. 2010, 13, 961-965
37. 6 serotonin receptor antagonist SB-271046 attenuates development and expression of nicotine-induced locomotor sensitization in Wistar rats Neuropharmacology 2011, 61, 451-457
38. Taylor, D.; McAskill, R. Atypical antipsychotics and weight gain: a systematic review Acta Psychiatr. Scand. 2000, 101, 416-432 (Pubitemid 30365564)
39. 6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders Pharmacol. Ther. 2008, 117, 207-231
40. 6 receptor as a target for developing novel antiobesity drugs Int. Rev. Neurobiol. 2011, 96, 73-109
41. 6 receptor ligands J. Med. Chem. 2005, 48, 1781-1795 (Pubitemid 40396311)
42. 6) receptor antagonists J. Med. Chem. 2005, 48, 4216-4219 (Pubitemid 40884923)
43. 6 receptor J. Neurochem. 1998, 71, 2169-2177 (Pubitemid 28491575)
44. Data from Thomson Reuters Integrity, http://www.thomsonreutersintegrity. com/.
45. 6 antagonist: one-step synthesis of (E)-3-(benzenesulfonyl)-2-(methylsulfanyl)pyrido[1,2-a]pyrimidin-4- ylidenamine from 2-(benzenesulfonyl)-3,3-bis(methylsulfanyl)acrylonitrile J. Med. Chem. 2003, 46, 4834-4837 (Pubitemid 37352023)
46. 6 ligands from common feature pharmacophore hypotheses J. Chem. Inf. Model. 2008, 48, 197-206 (Pubitemid 351271065)
47. 6 receptor antagonists Bioorg. Med. Chem. 2010, 18, 5282-5290
48. 6 receptor antagonists J. Comb. Chem. 2010, 12, 445-452
49. 6 receptor antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2133-2136
50. 6 for antagonism Bioorg. Med. Chem. Lett. 2010, 20, 3436-3440
51. Aronov, A. M. Predictive in silico modeling for hERG channel blockers Drug Discovery Today: BIOSILICO 2005, 10, 149-155 (Pubitemid 40247813)
52. Farid, R.; Day, T.; Friesner, R. A.; Pearlstein, R. A. New insights about HERG blockade obtained from protein modeling, potential mapping, and docking studies Bioorg. Med. Chem. 2006, 14, 3160-3173
53. Imai, Y. N.; Ryu, S.; Oiki, S. Docking model of drug binding to the human ether-a-go-go potassium channel guided by tandem dimmer mutant patch-clamp data: a synergistic approach J. Med. Chem. 2009, 52, 1630-1638
54. Kongsamut, S.; Kang, J.; Chen, X.-L.; Roehr, J.; Rampe, D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs Eur. J. Pharmacol. 2002, 450, 37-41
55. Silvestre, J. S.; Prous, J. R. Comparative evaluation of potassium hERG channel blockade by antipsychotics Methods Find. Exp. Clin. Pharmacol. 2007, 29, 457-465 (Pubitemid 350157134)
56. 1 cannabinoid receptor antagonists J. Med. Chem. 2004, 47, 627-643 (Pubitemid 38129720)
57. Grosscurt, A. C.; van Hes, R.; Wellinga, K. 1-Phenylcarbamoyl-2- pyrazolines, a new class of insecticides. 3. Synthesis and insecticidal properties of 3,4-diphenyl-1-phenylcarbamoyl-2-pyrazolines J. Agric. Food. Chem. 1979, 27, 406-409
58. a could be determined experimentally between pH 2 and pH 12, confirming calculations previously carried out with hit structure 1. Consequently, the pH-metric log P of 6 could not be determined. Alternatively, the HPLC log? D was determined to be 2.4 at Sirius (http://www.sirius-analytical.com), being in reasonable agreement with the AlogP of 2.73 as calculated with Pipeline Pilot (http://accelrys.com).
59. Currents were measured by using the whole-cell variant of the patch clamp method according to the method described in the following: Crumb, W.; Llorca, P.-M.; Lancon, C.; Thomas, G. P.; Garay, R. P.; Hameg, A. Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs Eur. J. Pharmacol. 2006, 532, 270-278
60. http://www.cerep.fr/Cerep/Users/index.asp.
61. Topiol, S.; Sabio, M. X-ray structure breakthroughs in the GPCR transmembrane region Biochem. Pharmacol. 2009, 78, 11-20
62. For a comprehensive consideration of the effects of intramolecular hydrogen bonding on conformational restrictions in target-ligand interactions and on ligand physicochemical properties see the following: Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601-2611
63. Jansma, A.; Zhang, Q.; Li, B.; Ding, Q.; Uno, T.; Bursulaya, B.; Liu, Y.; Furet, P.; Gray, N.; Geierstanger, H. Verification of a designed intromolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance J. Med. Chem. 2007, 50, 5875-5877
64. Flack, H. D. On enantiomorph-polarity estimation Acta Crystallogr., Sect. A 1983, 39, 876-881
65. Hooft, R. W. W.; Straver, L. H.; Spek, A. L. Determination of absolute structure using Bayesian statistics on Bijvoet differences J. Appl. Crystallogr. 2008, 41, 96-103
66. MetaSite, version 2.7.5; Molecular Discovery Ltd.: Perugia, Italy, 2006.
67. For more background, see the following: Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J. Med. Chem. 2005, 48, 6970-6979 (Pubitemid 41533118)
68. http://www.cyprotex.com/cloescreen/in-vitro-metabolism/ cytochrome-p450-reaction-phenotyping/.
69. Carsky, P.; Hünig, S.; Stemmler, I.; Scheutzow, D. Two step redox systems, XXVII. Vinylogous bipyridyls and biquinolyls; syntheses and UV/VIS-spectra Liebigs Ann. Chem. 1980, 2, 291-304
70. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drug Targeting 1998, 6, 151-165 (Pubitemid 29033982)
71. Tsai, T.-Y.; Shia, K.-S.; Liu, H.-J. A facile method for the construction of highly substituted acetonitriles and olefins. Malononitriles as acetonitrile carbanion and alkylidene dianion equivalents Synlett 2003, 97-101 (Pubitemid 36110806)
72. Diez-Barra, E.; de la Hoz, A.; Moreno, A.; Sanchez-Verdu, P. Phase transfer catalysis without solvent. Synthesis of cycloalkane-1,1-dicarbonitriles and alkanetetracarbonitriles J. Chem. Soc., Perkin Trans. 1 1991, 4, 2593-2596
73. Briggs, C. B. A.; Newington, I. M.; Pitt, A. R. Synthesis and properties of some novel nonionic polyol surfactants J. Chem. Soc., Chem. Comm. 1995, 3, 379-380
74. Bitha, P.; Child, R. G.; Hlavka, J. J.; Lin, Y.-I. Platinum Complexes of Amines with Dibasic Acids. U.S. Patent 4,675,336, 1987.
75. Stroefer, E.; Rohr, W.; Rotermund, G. W.; Fischer, R.; Neudert, R. Preparation of 1-Pyrazolines. U.S. Patent 4,788,293, 1988.
76. http://www.cyprotex.com/cloescreen/protein-binding/plasma-protein- binding/.
77. Hey, J. A.; Pardo, M. D.; Sherwood, J.; Kreutner, W.; Egan, R. W. Comparative analysis of the cardiotoxic proclivities of second generation antihistamines in an experimental model of adverse clinical ECG effects Arzneim. Forsch. 1996, 46, 153-158 (Pubitemid 26079145)
78. Hey, J. A.; Pardo, M. D.; Kreutner, W.; Egan, R. W. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes Arzneim. Forsch. 1996, 46, 159-163. In the meantime it has been shown that the use of telemetry transducers enables investigation of potential test substance effect in the absence of anesthesia in freely moving animals (Pubitemid 26078238)
79. Read, K. D.; Braggio, S. Assessing brain free fraction in early drug discovery Expert Opin. Drug Metab. Toxicol. 2010, 6, 337-344
80. 6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats Neurobiol. Learn. Mem. 2011, 96, 392-402
81. Spek, A. L. Single-crystal structure validation with the program PLATON J. Appl. Crystallogr. 2003, 36, 7-13
82. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J. Clin. Invest 1995, 96, 1698-1705
83. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor Science 2007, 318, 1258-1265 (Pubitemid 350172884)
84. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Ø crystal structure J. Mol. Biol. 2004, 342, 571-583 (Pubitemid 39149759)
85. Deupi, X.; Olivella, M.; Govaerts, C.; Ballesteros, J. A.; Campillo, M.; Pardo, L. Ser and Thr residues modulate the conformation of pro-kinked transmembrane alpha-helices Biophys. J. 2004, 86, 105-115 (Pubitemid 38067440)
86. http://www.schrodinger.com.
87. 6 receptor Mol. Pharmacol. 1997, 52, 515-523 (Pubitemid 27412978)
88. 6 receptor antagonists. Molecular mechanisms of receptor inactivation J. Med. Chem. 2010, 53, 1357-1369
89. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748 (Pubitemid 27170693)
90. Bazett, H. C. An analysis of the time relations of the electrocardiograms Heart 1920, 7, 353-370
91. Liu, X.; Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Worboys, P. D.; Monshouwer, M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid Drug Metab. Dispos. 2009, 37, 787-793